Clinical Presentations and Outcomes in Transplant Patients With COVID-19: A Systematic Review and Meta-Analysis

Abstract Introduction: Transplant patients are a vulnerable group due to their immunocompromised status. Understanding how COVID-19 can present in this group is clinically important. Therefore, we conduct a systematic review and meta-analysis on clinical features and management of transplant patients with COVID-19.Methods: Five databases were searched in May 2020 to include all relevant studies reporting clinical features or outcomes of COVID-19 infection in transplant patients. Data on clinical presentation, outcomes, lab values, imaging, and drug regimen were extracted. CMA software was used for meta-analysis. Protocol was registered in PROSPERO (CRD42020189458).Results: A total of 49 studies were finally included for analysis. Patients mainly complained from fever with event rate 74.40 % (95% CI= 69.4-78.8), cough 61.10% (95% CI= 55.8-66), and dyspnea 46.60% (95% CI= 69.4-78.8). Blood urea nitrogen 78.90% (95% CI= 54.7-92), ESR 78.10% (95% CI=52.3-92.1), and D-dimer 74.10% (95 % CI= 53-87.9) were the most elevated observed laboratory values. Ground glass opacities (GGO) were observed with event rate 68.10% (95% CI= 20.4-94.9). For treatment, immunosuppressants were used in 88.80% (95% CI= 77.6-94.8) of patients, followed by antibiotics and antiviral drugs 68.40% (95% CI= 52.4-80.9), 66.80% (95% CI = 45-83.2), respectively. Mechanical ventilation was used in 26.30% (95% CI=21-32.4) patients while 33.7% (95% CI= 20.7-49.9) intubated. Rejection occurred in 11% (95% CI= 4.4-25) of the patients. Finally, 18.20% (95% CI= 12.6-25.7) died. Conclusion: Clinical characteristics and management in transplant COVID patients suggest the similar course in non-transplant. Fever, cough, dyspnoea, elevated blood urea nitrogen level, elevated CRP, elevated d-dimer, GGO, and consolidation were found to be the most frequent abnormalities. No direct, comparative analysis with non-transplant COVID population limited our results; however, numerous studies that examined the infected general population found similar, less augmented findings. Most of the included sample were kidney transplant patients; therefore, more studies are needed to address other types of COVID-19 infected transplant patients.

Download Full-text

The Efficacy of Triptolide in Preventing Diabetic Kidney Diseases: A Systematic Review and Meta-Analysis

Frontiers in Pharmacology ◽

10.3389/fphar.2021.728758 ◽

2021 ◽

Vol 12 ◽

Author(s):

Dongning Liang ◽

Hanwen Mai ◽

Fangyi Ruan ◽

Haiyan Fu

Keyword(s):

Systematic Review ◽

Serum Creatinine ◽

Blood Urea Nitrogen ◽

Meta Analysis ◽

Renin Angiotensin System ◽

Risk Of Bias ◽

Urea Nitrogen ◽

Angiotensin System ◽

Meta Regression ◽

Ras Inhibitors

Ethnopharmacological Relevance: Triptolide (TP), the primary biologically active ingredient of Tripterygium wilfordii Hook F (TWHF), possesses the potential to solve the shortcomings of TWHF in treating diabetic kidney disease (DKD) in the clinic.Aim of the Study: We conducted a meta-analysis to evaluate the efficacy of TP in treating DKD and offer solid evidence for further clinical applications of TP.Materials and Methods: Eight databases (CNKI, VIP, CBM, WanFang, PubMed, Web of Science, EMBASE, and Cochrane library) were electronically searched for eligible studies until October 17, 2020. We selected animal experimental studies using TP versus renin–angiotensin system inhibitors or nonfunctional liquids to treat DKD by following the inclusion and exclusion criteria. Two researchers independently extracted data from the included studies and assessed the risk of bias with the Systematic Review Centre for Laboratory Animal Experimentation Risk of Bias tool. Fixed-effects meta-analyses, subgroup analyses, and meta-regression were conducted using RevMan 5.3 software. Inplasy registration number: INPLASY2020100042.Results: Twenty-six studies were included. Meta-analysis showed that TP significantly reduced albuminuria (14 studies; standardized mean difference SMD: −1.44 [−1.65, −1.23], I2 = 87%), urine albumin/urine creatinine ratio (UACR) (8 studies; SMD: –5.03 [–5.74, −4.33], I2 = 84%), total proteinuria (4 studies; SMD: –3.12 [–3.75, −2.49], I2 = 0%), serum creatinine (18 studies; SMD: –0.30 [–0.49, −0.12], I2 = 76%), and blood urea nitrogen (12 studies; SMD: –0.40 [–0.60, −0.20], I2 value = 55%) in DKD animals, compared to the vehicle control. However, on comparing TP to the renin–angiotensin system (RAS) inhibitors in DKD treatment, there was no marked difference in ameliorating albuminuria (3 studies; SMD: –0.35 [–0.72, 0.02], I2 = 41%), serum creatinine (3 studies; SMD: –0.07 [–0.62, 0.48], I2 = 10%), and blood urea nitrogen (2 studies; SMD: –0.35 [–0.97, 0.28], I2 = 0%). Of note, TP exhibited higher capacities in reducing UACR (2 studies; SMD: –0.66 [–1.31, −0.01], I2 = 0%) and total proteinuria (2 studies; SMD: –1.18 [–1.86, −2049], I2 = 0%). Meta-regression implicated that the efficacy of TP in reducing DKD albuminuria was associated with applied dosages. In addition, publication bias has not been detected on attenuating albuminuria between TP and RAS inhibitors after the diagnosis of DKD.Systematic Review Registration:https://clinicaltrials.gov/, identifier INPLASY2020100042

Download Full-text

The Chronic Kidney Disease and Acute Kidney Injury Involvement in COVID-19 Pandemic: A Systematic Review and Meta-analysis

10.1101/2020.04.28.20083113 ◽

2020 ◽

Cited By ~ 3

Author(s):

Ya-Fei Liu ◽

Zhe Zhang ◽

Xiao-Li Pan ◽

Guo-Lan Xing ◽

Ying Zhang ◽

...

Keyword(s):

Systematic Review ◽

Chronic Kidney Disease ◽

Acute Kidney Injury ◽

Kidney Disease ◽

Serum Creatinine ◽

Blood Urea Nitrogen ◽

Meta Analysis ◽

Kidney Injury ◽

Urea Nitrogen ◽

Severe Group

ABSTRACTAimThe aim of this study was to uncover whether kidney diseases were involved in COVID-19 pandemic from a systematic review.MethodsThe studies reported the kidney outcomes in different severity of COVID-19 were included in this study. Standardized mean differences or odds ratios were calculated by employing Review Manager meta-analysis software.ResultsThirty-six trials were included in this systematic review with a total of 6395 COVID-19 patients. The overall effects indicated that the comorbidity of chronic kidney disease (CKD) (OR = 3.28), complication of acute kidney injury (AKI) (OR = 11.02), serum creatinine (SMD = 0.68), abnormal serum creatinine (OR = 4.86), blood urea nitrogen (SMD = 1.95), abnormal blood urea nitrogen (OR = 6.53), received continuous renal replacement therapy (CRRT) (OR = 23.63) was significantly increased in severe group than that in nonsevere group. Additionally, the complication of AKI (OR = 13.92) and blood urea nitrogen (SMD = 1.18) were remarkably elevated in critical group than that in severe group.ConclusionCKD and AKI are susceptible to occur in patients with severe COVID-19. CRRT is applied frequently in severe COVID-19 patients than that in nonsevere COVID-19 patients. The risk of AKI is higher in critical group than that in severe group.

Download Full-text

The chronic kidney disease and acute kidney injury involvement in COVID-19 pandemic: A systematic review and meta-analysis

PLoS ONE ◽

10.1371/journal.pone.0244779 ◽

2021 ◽

Vol 16 (1) ◽

pp. e0244779

Author(s):

Ya-Fei Liu ◽

Zhe Zhang ◽

Xiao-Li Pan ◽

Guo-Lan Xing ◽

Ying Zhang ◽

...

Keyword(s):

Systematic Review ◽

Chronic Kidney Disease ◽

Acute Kidney Injury ◽

Kidney Disease ◽

Serum Creatinine ◽

Blood Urea Nitrogen ◽

Meta Analysis ◽

Kidney Injury ◽

Urea Nitrogen ◽

Severe Group

Background Currently, the SARS-CoV-2 promptly spread across China and around the world. However, there are controversies about whether preexisting chronic kidney disease (CKD) and acute kidney injury complication (AKI) are involved in the COVID-19 pandemic. Measurements Studies reported the kidney outcomes in different severity of COVID-19 were included in this study. Standardized mean differences or odds ratios were calculated by employing Review Manager meta-analysis software. Results Thirty-six trials were included in this systematic review with a total of 6395 COVID-19 patients. The overall effects indicated that preexisting CKD (OR = 3.28), complication of AKI (OR = 11.02), serum creatinine (SMD = 0.68), abnormal serum creatinine (OR = 4.86), blood urea nitrogen (SMD = 1.95), abnormal blood urea nitrogen (OR = 6.53), received continuous renal replacement therapy (CRRT) (OR = 23.63) were significantly increased in severe group than that in nonsevere group. Additionally, the complication of AKI (OR = 13.92) and blood urea nitrogen (SMD = 1.18) were remarkably elevated in the critical group than that in the severe group. Conclusions CKD and AKI are susceptible to occur in patients with severe COVID-19. CRRT is applied frequently in severe COVID-19 patients than that in nonsevere COVID-19 patients. The risk of AKI is higher in the critical group than that in the severe group.

Download Full-text

D-Dimer, Disease Severity, and Deaths (3D-Study) in Patients with COVID-19: A Systematic Review and Meta-Analysis

SSRN Electronic Journal ◽

10.2139/ssrn.3696621 ◽

2020 ◽

Author(s):

Seshadri Reddy Varikasuvu ◽

Naveen Dutt ◽

Saurabh Varshney ◽

Shahir Asfahan ◽

Paresh P. Kulkarni ◽

...

Keyword(s):

Systematic Review ◽

Disease Severity ◽

Meta Analysis ◽

D Dimer

Download Full-text

Clinical features and outcomes of pregnant women with COVID-19: a systematic review and meta-analysis

BMC Infectious Diseases ◽

10.1186/s12879-020-05274-2 ◽

2020 ◽

Vol 20 (1) ◽

Cited By ~ 9

Author(s):

Yi-jie Gao ◽

Lei Ye ◽

Jia-shuo Zhang ◽

Yang-xue Yin ◽

Min Liu ◽

...

Keyword(s):

Systematic Review ◽

Pregnant Women ◽

Clinical Features ◽

Meta Analysis

Download Full-text

Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis

BMC Geriatrics ◽

10.1186/s12877-021-02261-3 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Sunny Singhal ◽

Pramod Kumar ◽

Sumitabh Singh ◽

Srishti Saha ◽

Aparajit Ballav Dey

Keyword(s):

Systematic Review ◽

Older Adults ◽

Critically Ill ◽

Clinical Features ◽

Older Patients ◽

Clinical Characteristics ◽

Meta Analysis ◽

Severe Infection ◽

Factors Affecting ◽

Pooled Prevalence

Abstract Background Few studies have focused on exploring the clinical characteristics and outcomes of COVID-19 in older patients. We conducted this systematic review and meta-analysis to have a better understanding of the clinical characteristics of older COVID-19 patients. Methods A systematic search of PubMed and Scopus was performed from December 2019 to May 3rd, 2020. Observational studies including older adults (age ≥ 60 years) with COVID-19 infection and reporting clinical characteristics or outcome were included. Primary outcome was assessing weighted pooled prevalence (WPP) of severity and outcomes. Secondary outcomes were clinical features including comorbidities and need of respiratory support. Result Forty-six studies with 13,624 older patients were included. Severe infection was seen in 51% (95% CI– 36-65%, I2–95%) patients while 22% (95% CI– 16-28%, I2–88%) were critically ill. Overall, 11% (95% CI– 5-21%, I2–98%) patients died. The common comorbidities were hypertension (48, 95% CI– 36-60% I2–92%), diabetes mellitus (22, 95% CI– 13-32%, I2–86%) and cardiovascular disease (19, 95% CI – 11-28%, I2–85%). Common symptoms were fever (83, 95% CI– 66-97%, I2–91%), cough (60, 95% CI– 50-70%, I2–71%) and dyspnoea (42, 95% CI– 19-67%, I2–94%). Overall, 84% (95% CI– 60-100%, I2–81%) required oxygen support and 21% (95% CI– 0-49%, I2–91%) required mechanical ventilation. Majority of studies had medium to high risk of bias and overall quality of evidence was low for all outcomes. Conclusion Approximately half of older patients with COVID-19 have severe infection, one in five are critically ill and one in ten die. More high-quality evidence is needed to study outcomes in this vulnerable patient population and factors affecting these outcomes.

Download Full-text